Terrie Curran, Phathom Pharmaceuticals CEO (Arcutis)
February 10, 2023 07:27 AM EST
FDA+

Still no green light for Phath­om's gas­troin­testi­nal drugs af­ter im­pu­ri­ties found in batch­es

Katherine Lewin

News Reporter

Phath­om Phar­ma­ceu­ti­cals is still work­ing out the kinks of launch­ing two al­ready-ap­proved drugs for a bac­te­r­i­al in­fec­tion and snag­ging an NDA ap­proval for an­oth­er gas­troin­testi­nal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times